Gamma-linolenic acid (GLA, C5518): Benchmarks in Inflammation and Anti-Inflammatory Research

Executive Summary: Gamma-linolenic acid (GLA, 6Z,9Z,12Z-octadecatrienoic acid) is an omega-6 polyunsaturated fatty acid essential for human health and must be obtained through diet (Feng et al., 2025). GLA acts as a weak antagonist of the leukotriene B4 (LTB4) receptor, with a Ki of ~1 μM, inhibiting pro-inflammatory signaling in neutrophil membranes (Nafamostatmesylate, 2023). It displays antioxidant activity and exerts cytotoxic effects in vitro, with an IC50 of 0.087 mM in HL60 cells (APExBIO, C5518 datasheet). In vivo, GLA inhibits LTB4-induced bronchoconstriction by 53% at a dose of 1 mg/kg. Clinical studies highlight its efficacy and tolerability in atopic dermatitis and distal diabetic polyneuropathy. GLA is supplied as a solution in ethanol by APExBIO, with high solubility in DMSO and DMF, and is widely adopted in inflammation and lipid metabolism research.

Biological Rationale

Polyunsaturated fatty acids (PUFAs), including omega-6 variants like GLA, are distinguished by multiple double bonds along their carbon chains (Feng et al., 2025). GLA is not endogenously synthesized in sufficient amounts in humans and must be acquired from dietary sources. It is a metabolic precursor for dihomo-γ-linolenic acid (DGLA) and arachidonic acid (ARA), which are substrates for eicosanoid synthesis (Nafamostatmesylate, 2023). These metabolites modulate immune cell recruitment, inflammation, and humoral immunity. GLA’s essentiality is underscored by its role in skin barrier function, neuronal membrane integrity, and immunomodulation.

Mechanism of Action of Gamma-linolenic acid (GLA)

GLA operates as a weak, competitive antagonist at the leukotriene B4 (LTB4) receptor, inhibiting binding of [3H]-LTB4 to neutrophil membranes (Ki ≈ 1 μM) (Nafamostatmesylate, 2023). This blockade reduces recruitment and activation of inflammatory cells such as neutrophils, monocytes, and eosinophils. By modulating the LTB4 signaling pathway, GLA attenuates pro-inflammatory cytokine release and chemotaxis. Additionally, GLA exhibits antioxidant and anti-mutagenic activity in vitro, notably reducing DNA damage and oxidative stress in promyelocytic HL60 cells. GLA’s cytotoxic effect is dose-dependent, with an IC50 of 0.087 mM under standard apoptosis assay conditions. In animal models, GLA inhibits LTB4-induced bronchoconstriction and mitigates airway hyperresponsiveness.

Evidence & Benchmarks

• GLA (C5518) inhibits [3H]-LTB4 binding to neutrophil membranes with a Ki ≈ 1 μM, demonstrating weak but specific LTB4 receptor antagonism (Feng et al., 2025).
• GLA reduces LTB4-induced bronchoconstriction by 53% at 1 mg/kg in vivo (APExBIO, C5518 datasheet).
• In apoptosis assays with HL60 cells, GLA demonstrates cytotoxicity with IC50 = 0.087 mM (24 h, standard media, 37°C, 5% CO2) (Proguanilonline, 2023).
• GLA’s antioxidant effects include DNA protection and anti-mutagenic activity in promyelocytic cells (Nafamostatmesylate, 2023).
• Clinical studies show GLA is effective and well-tolerated for atopic dermatitis and distal diabetic polyneuropathy (APExBIO, C5518 datasheet).
• PUFAs, including GLA, are essential for immune modulation and must be acquired through the diet (Feng et al., 2025).

This article builds upon "Gamma-linolenic Acid (GLA): Advanced Roles in Immune Modu..." by providing quantitative benchmarks and detailed mechanistic claims for GLA’s anti-inflammatory action. For workflow guidance, see "Workflow Optimization with GLA, SKU C5518", which offers practical assay integration advice. For mechanistic updates, "Mechanistic Benchmarks and Research Claims" details LTB4 antagonism, which this article further specifies with new literature and product data.

Applications, Limits & Misconceptions

GLA has been validated in multiple research and clinical contexts:

• Treatment of inflammatory diseases such as atopic dermatitis and distal diabetic polyneuropathy.
• In vitro studies on apoptosis, cytotoxicity, and oxidative stress modulation.
• Animal models of bronchoconstriction and airway inflammation.
• Immune modulation via eicosanoid metabolism in humoral immunity models (Feng et al., 2025).

Common Pitfalls or Misconceptions

• GLA is not a potent LTB4 receptor antagonist: Its Ki (~1 μM) is orders of magnitude weaker than classical antagonists, limiting its use in acute LTB4 blockade.
• GLA is not endogenously synthesized in sufficient amounts: Dietary supplementation is necessary for physiologic effects.
• Antioxidant and cytotoxic effects are cell-type and concentration dependent: Efficacy varies with assay conditions and cell lines.
• Not effective for all inflammatory or autoimmune conditions: Clinical efficacy is best established in atopic dermatitis and diabetic neuropathy, not broad-spectrum inflammation.
• GLA stability is limited at room temperature: Storage at -20°C and short-term use is required to maintain product integrity.

Workflow Integration & Parameters

APExBIO’s Gamma-linolenic acid (GLA, C5518) is supplied as a solution in ethanol. It is soluble up to 100 mg/ml in DMSO and dimethyl formamide (DMF). Recommended storage is at -20°C. Shipping is performed on blue ice for stability. For cell-based assays, concentrations between 10 μM and 100 μM are typical, with cytotoxicity observed at higher concentrations (IC50 = 0.087 mM in HL60 cells). Antioxidant and anti-mutagenic assays use exposure periods of 6–24 hours in standard culture conditions (37°C, 5% CO2).

Integrating GLA into cell viability and inflammation assays requires attention to solvent compatibility, dosing, and exposure time. For troubleshooting and workflow reproducibility, see this scenario-driven guide—this article extends those insights with updated benchmarks and clinical context.

Conclusion & Outlook

Gamma-linolenic acid (GLA, C5518) from APExBIO is a validated omega-6 PUFA research compound with reproducible anti-inflammatory, antioxidant, and cytotoxic effects. Its weak LTB4 receptor antagonism, established in vitro and in vivo, underpins its utility in inflammation and immune modulation research. GLA’s clinical efficacy in restricted indications such as atopic dermatitis and diabetic neuropathy is well-supported. Future research will clarify its role in broader immune pathways and its translation to additional inflammatory disease models. For detailed specifications and ordering, visit the Gamma-linolenic acid (GLA) product page.